TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of cancer~* Scheduled to receive inpatient chemotherapy containing at least moderately emetogenic agents~  * May be given for adjuvant, neoadjuvant, curative, or palliative intent~ * May be given orally, IV, or by continuous infusion on ≥ 1 day~* Scheduled to receive 5-HT3 receptor antagonist antiemetic (e.g., ondansetron, granisetron, palonosetron, dolasetron mesylate, or dexamethasone with or without a benzodiazepine) on the day of chemotherapy~* Self-report of at least mild nausea (for which the patient feels needs rescuing) or moderate nausea (a score of ≥ 2 on a 4-point Likert scale) OR has had ≥ 1 episode of emesis since receiving chemotherapy~* No history of chronic nausea and/or vomiting (without chemotherapy), anticipatory nausea and/or vomiting, or emesis within 24 hours before chemotherapy~* No symptomatic brain metastases~PATIENT CHARACTERISTICS:~* Able to understand English~* Not pregnant or nursing~* Negative pregnancy test~* No clinical evidence of current or impending bowel obstruction (i.e., tumor pressing on the bowel)~* No allergy or intolerance to study drugs~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Prior chemotherapy allowed~* No aprepitant as prophylaxis or rescue treatment during the current course of chemotherapy (other than as a part of study therapy)~* Not scheduled to receive a dopamine antagonist after chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Fosaprepitant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Virtual Reality Education Module in Reducing Anxiety and Increasing Knowledge in Patients With Prostate Cancer Undergoing Radiation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking males capable of giving informed consent~* Must be able to read English language~* Receiving pre-treatment cone beam and volumetric modulated arc therapy (VMAT) for prostate cancer on the A or B treatment machines at the Bodine Center~* Must be able to walk two city blocks~* Must not have any auditory or visual deficits~Exclusion Criteria:~* If inclusion criteria are not met~* Previous radiation therapy treatment~* Employment in radiation oncology

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive care (virtual reality education module) (Type: EXPERIMENTAL): After undergoing a previously planned CT simulation scan, patients complete a virtual reality education module to learn more about radiation therapy for prostate cancer. Patients also complete questionnaires before and after the module.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Histologically or cytologically confirmed adenocarcinoma of the pancreas~* Locally advanced or metastatic pancreatic cancer~* Measurable primary pancreatic cancer or metastasis~* No previous chemotherapy either in an adjuvant or metastatic setting~* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1~* Adequate bone marrow: granulocyte count ≥ 1.5 G/L; and platelet count ≥ 100 G/L~* Adequate liver function: bilirubin ≤ 2 times the upper limit of the normal range, transaminases (AST and ALT) ≤ 3 times the upper limit of the normal range~* Adequate renal function: calculated clearance rate \> 60 m.mn-1 (Estimated glomerular filtration rate using Modification of Diet in Renal Disease (MDRD) formula or Cockcroft-Gault formula)~* Women of childbearing potential must use an effective birth control method~Exclusion Criteria:~* Endocrine or acinar pancreatic carcinoma~* Pancreatic metastasis of other primary tumors~* Previous radiotherapy for measurable lesions~* Previous chemotherapy~* History of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis~* Other prior malignancy. Adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or any other cancer from which the patient has been disease free for \> 5 years are allowed.~* Known HIV disease requiring antiretroviral treatment~* Hemorrhagic diathesis~* Aspirin with a daily dose \> 75 mg~* Curative dose of LMWH~* Recent venous thromboembolism (\< 1 year)~* Patients under VKA~* Lesion of the digestive tract that could be hemorrhagic with clopidogrel treatment~* Active infection~* Chronic diarrhea~* Cardiac disease with a left ventricular ejection fraction below 45%~* Hypersensitivity to clopidogrel or its excipients~* Patients with severe hepatic impairment~* Patients who are pregnant or breast feeding, or who are not using effective birth control methods~* Participation in another clinical research protocol, participation in a trial of routine care is authorized at the same time as PANCREADOGREL~* Patient under tutorship or curatorship~* Patients unwilling or unable to comply with the protocol~* Not affiliated to health system (bénéficiaire ou ayant droit)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: EXPERIMENTAL): Clopidogrel tablets 75 mg for six months:
- Comparator (Type: PLACEBO_COMPARATOR): Placebo tablet 75 mg for six months:

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive-Behavioural Therapy as a Preventive Treatment for Post Traumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presenting to the emergency department at the Karolinska University hospital Solna in the past 72 hours before the intervention~* Meets diagnostic criterion A for post-traumatic stress disorder in the fifth version of Diagnostic and Statistical Manual of Mental Disorders, DSM-5~Exclusion Criteria:~* Do not want to participate in the study~* Ongoing intoxication (e.g. severe alcohol intoxication)~* Other serious psychiatric comorbidity that demands attention (e.g. manic episode, acute suicidal ideation)~* Not oriented~* Not having a memory ot the tramatic event

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Modified prolonged exposure therapy (Type: EXPERIMENTAL): Participants will receive three sessions of modified prolonged exposure therapy.
- Attention control (Type: PLACEBO_COMPARATOR): Participants will receive three sessions of supportive counselling and psychoeducation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Responsive Feeding of Infants With Expressed Milk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria: Mother-infant dyads are eligible to participate if:~* mother is aged 19 years or older,~* dyads currently live in the Halifax Regional Municipality in Nova Scotia,~* mother has no chronic diseases,~* the baby is a healthy singleton baby who is younger than 6 weeks of age, and is fed mother's milk directly from the breast and from a bottle,~* mother plans to exclusively feed their baby mother's own milk up to 6 months,~* mother has/had an older child whom they successfully fed mother's own milk for a minimum of 6 months,~* mother is willing to participate in three 3-day study sessions and monthly measurement sessions, and~* mother provides informed consent for herself and her infant to participate.~Exclusion criteria: Mother-infant dyads are ineligible to participate if:~* the baby was born preterm (earlier than 37 weeks gestation),~* the baby was born outside the healthy weight range of 2,500 - 4,000 g (5lb 8oz to 8lb 13oz),~* the baby has a developmental delay diagnosed before the time of enrolment,~* the baby is currently receiving any medical treatment except for vitamin D supplementation (no more than 400 IU/day),~* the mother sought prescription medical treatment for lactation (e.g. domperidone, antibiotics, prescription nipple ointment), or~* the mother plans to move in the 6 months after starting the study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Breastfeeding (Type: ACTIVE_COMPARATOR): Infant consumes mother's milk directly from the breast.
- Bottle-feeding (Type: EXPERIMENTAL): Infant consumes mother's expressed milk from a bottle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Oxford Signature vs. Conventional Global Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Intended for use in individuals with osteoarthritis or Avascular necrosis limited to the medial compartment of the knee that is also lacking patellofemoral or lateral compartment disease.~* Use of cementless femoral fixation is permitted outside of the United States if it complies with all local, state, and/or national and international regulations. The same technique must be used consistently throughout the course of the study with all cases~* Patients 21 and over~Exclusion Criteria:~* Use of Cementless Fixation in the United States~* Infection, sepsis or osteomyelitis~* Use in lateral compartment of the knee~* Rheumatoid arthritis or other forms of inflammatory joint disease~* Revision of failed prosthesis, failed upper tibial osteotomy, or post traumatic arthritis after tibial plateau fracture~* Insufficiency of the collateral, anterior, or posterior cruciate ligaments which would preclude stability of the device.~* Disease or damage to the lateral compartment of the knee~* Uncooperative patient or patient with neurologic disorders who is incapable of following directions~* Osteoporosis in the United States / Insufficient bone stock outside the United States~* Metabolic disorders which may impair bone formation~* Osteomalacia~* Distant foci of infections which may spread to implant site~* Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram~* Vascular insufficiency, muscular atrophy, neuromuscular disease.~* Incomplete or deficient soft tissue surrounding the knee.~* Charcot's disease~* A fixed varus deformity (not passively correctable) of greater than 15 degrees~* A flexion deformity greater than 15 degrees.~* Non-staged Bilateral patients~* Patients who refuse, cannot, or should not receive a CT or MRI. Since patients are randomized into treatment groups, all patients must be able to receive an MRI (should follow local MRI screening protocol). This excludes patients who have metal artifacts in the knee, patients who are too large to fit into the knee coil, patients with pacemakers, patients unable to lie still for the duration of the MRI, and patients who are claustrophobic.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Signature Custom Guides (Type: ACTIVE_COMPARATOR): Oxford Partial Knee implanted using Signature Custom Guides
- Conventional Instrumentation (Type: ACTIVE_COMPARATOR): Oxford Partial Knee implanted using Conventional Instrumentation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Nimodipine on the Postoperative Cognitive Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Glascow coma scale GCS 15 preoperatively~* American Society of Anesthesiologists ASA risk I - III~* planned brain surgery~* duration of procedure up to 4 hours.~Exclusion Criteria:~* blood pressure below 130/80 torr preoperatively~* previous vascular surgery~* concomitant use of antiepileptic drugs, rifampicin~* allergy to nimodipine~* known liver cirrhosis

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nimodipine group (Type: EXPERIMENTAL): 1 tbl of 30 mg nimodipine will be administered orally with premedication
- Control group (Type: EXPERIMENTAL): 1 tbl of placebo will be administered orally with premedication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* chronic fatigue syndrome/ myalgic encephalomyelitis (CFS/ME)~* moderate and serious CFS/ME severity~* age 18-66 years~* informed consent~Exclusion Criteria:~* patients with fatigue, not fulfilling criteria for CFS~* pregnancy or lactation~* previous malignant disease, except basal cell carcinoma of skin and cervical carcinoma in situ~* previous long-term systemic treatment with immunosuppressive drugs such as cyclosporine, azathioprin, mycophenolate mofetil, except steroids e.g. in obstructive lunge disease.~* demyelinating disease, such as multiple sclerosis.~* heart failure.~* endogenous depression.~* lack of ability to comply to the protocol.~* multi-allergy with risk of serious drug reaction~* reduced renal function (creatinine \> 1.5 x UNL)~* reduced liver function (bilirubin or transaminases \> 1.5 x UNL)~* HIV positivity. Evidence of clinically significant infection. Previous viral hepatitis with risk of reactivation. High risk of opportunistic infections. Latent tuberculosis must be treated before inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Study Arms:
- Etanercept (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) schizophrenia~* Total score on the PANSS Marder Negative Symptom Factor Scale (NSFS) ≥20~* Total score on the PANSS Marder Positive Symptom Factor Scale (PSFS) ≤ 30~* Receiving stable antipsychotic therapy for at least 8 weeks prior to screening~* Receiving a stable dose of other psychotropic agents for at least 8 weeks prior to screening~* Subject has had a stable residence or living arrangement for at least 8 weeks prior to screening and the residence or living arrangement is not anticipated to change for the duration of the study~* The subject or subject's legally acceptable representative has provided informed consent.~Exclusion Criteria:~* Current schizoaffective or bipolar disorder, panic disorder, obsessive compulsive disorder, evidence of mental retardation by history or clinical examination or known premorbid IQ ≤ 70~* Clinically significant suicidal ideation or suicide attempts, assaultive behavior or marked changes in mood within the 8 weeks prior to screening, or currently endorsing suicidal ideation in clinical exam~* Substance abuse (with the exception of nicotine or caffeine abuse) within the 8 weeks prior to screening, or during screening~* Substance dependence (with the exception of nicotine or caffeine dependence) within the 6 months prior to screening, or during screening~* Planning to initiate a smoking cessation therapy or otherwise substantially modify nicotine use during the study~* Positive urine drug test for substances of abuse (with the exception of positive screens for prescribed agents such as benzodiazepines).~* Other criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- AMG 747 - Dose 1 (Type: EXPERIMENTAL): None
- AMG 747 - Dose 2 (Type: EXPERIMENTAL): None
- AMG 747 - Dose 3 (Type: EXPERIMENTAL): None
- Placebo Comparator (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Patients with diabetic macular edema relevant to visual acuity~* OCT central retinal thickness ≥ 250µm~* HbA1c \> 6,5% at initial visit~* BCVA ≤0.8 and ≥0.05~* Age ≥18 years~* Written patient informed consent given~Exclusion Criteria:~* Previous treatment with intravitreal drugs in last 6 months~* Vitreous hemorrhage as a consequence of proliferative retinopathy~* Pregnancy~* Blood pressure of ≥ 180/100 (or uncontrolled pressures under pharmacological therapy)~* Chronic systemic or ocular inflammatory/autoimmune diseases (e.g. inflammatory bowel disease, Addison´s disease, Cushing Syndrome, Uveitis)~* Systemic cortisone or anti-VEGF therapy~* Acute systemic or ocular infectious diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regular Glycemic Control (Type: ACTIVE_COMPARATOR): Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen. Patients randomized into this group will be controlled by their general practitioner or private diabetologist (usual care). The glycemic control (blood measurements of HbA1c) will be performed at trial site (Department of diabetology, endocrinology and nutritional medicine) every 3 months. The site will not influence or change the diabetes medication given by general physician and serves as an observer only to monitor the diabetic control.
- Intensified Glycemic Control (Type: EXPERIMENTAL): Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen.~Patients randomized into this group will be controlled at the trial site (Department of diabetology, endocrinology and nutritional medicine) during first year monthly, in the second study year every 3 months. The individual HbA1c will be targeted according to the general status reflecting other risk factors for the vasculopathy (e.g. BMI, smoking, blood pressure, lipid status). All effort will be done to reach the target blood pressure ≤ 140/90 mmHg and blood triglyceride level \< 140 mg/dl: Further the patients will be educated to improve their eating habits in regard to reduce the carbohydrate intake.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues